Cannabis use and addiction: what Yale’s research found

A Yale School of Medicine report published on 30 July 2026 describes research finding partly distinct genetic and brain-related patterns for cannabis use and cannabis use disorder. The study was published in Neuropsychopharmacology.

The distinction in plain language

Trying or using cannabis and developing a disorder are different outcomes. The researchers combined genetic analyses with brain-imaging data to investigate those differences. Yale’s account describes the transition to disorder as more complex than simply an increase in use.

That does not mean the study can tell an individual whether they will develop an addiction. A research finding about patterns across groups is not an individual diagnosis or a guarantee of safety.

Human genetics, not a claim about a variety

This research concerns human susceptibility. It does not establish that a particular cannabis variety is safe, non-addictive or suitable for treatment. Our earlier article connected the findings too loosely to plant breeding and commercial product decisions; those passages have been removed.

How to read the finding

Start with Yale’s account and its link to the study. Keep the measured outcome in view when reading a headline: a finding about use cannot automatically be applied to disorder, and neither should be converted into a medical claim about a product.

Our article on interpreting cannabis health evidence discusses the related difference between an observation, an association and a demonstrated cause.

Reviewed 14 October 2026. This article explains a research report and does not provide an individual risk assessment.